Anti-GDF-15 antibodies

US12258391B2 · kind B2 · utility

Assignee

• AVEO Pharmaceuticals, Inc. · US

Inventors

• Lorena Lerner · Newton, US
• Sandra Abbott · Boston, US
• Ailin Bai · Newton, US
• Ting Chen · Austin, US
• Maria Isabel Chiu · Boston, US
• Qing Liu · Acton, US
• Laura Poling · Boston, US
• Nianjun Tao · Watertown, US
• Solly Weiler · Newton, US
• Zhigang Weng · Cambridge, US
• William M. Winston, Jr. · Marlborough, US
• Jeno Gyuris · Lincoln, US

Key dates

• Filing date: Jun 16, 2023
• Grant date: Mar 25, 2025
• Expiry date: Jun 16, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/63
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.